Charles Schwab
BBIO icon

Charles Schwab’s BridgeBio Pharma BBIO Stock Holding History

Charles Schwab’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$127M Sell
1,709,417
-266,677
-13% -$18.7M 0.02% 648
2026
Q1 		$147M Buy
1,976,094
+11,675
+0.6% +$846K 0.02% 543
2025
Q4 		$150M Buy
1,964,419
+39,221
+2% +$2.57M 0.02% 527
2025
Q3 		$100M Buy
1,925,198
+593,725
+45% +$29M 0.02% 715
2025
Q2 		$57.5M Buy
1,331,473
+49,244
+4% +$1.79M 0.01% 1015
2025
Q1 		$44.3M Sell
1,282,229
-24,536
-2% -$827K 0.01% 1154
2024
Q4 		$35.9M Buy
1,306,765
+21,963
+2% +$568K 0.01% 1356
2024
Q3 		$32.7M Buy
1,284,802
+95,605
+8% +$2.51M 0.01% 1399
2024
Q2 		$30.1M Buy
1,189,197
+141,160
+13% +$3.86M 0.01% 1412
2024
Q1 		$32.4M Sell
1,048,037
-75,183
-7% -$2.56M 0.01% 1309
2023
Q4 		$45.3M Buy
1,123,220
+66,945
+6% +$2.01M 0.01% 1048
2023
Q3 		$27.9M Buy
1,056,275
+93,324
+10% +$2.65M 0.01% 1279
2023
Q2 		$16.6M Buy
962,951
+38,129
+4% +$574K ﹤0.01% 1621
2023
Q1 		$15.3M Buy
924,822
+128,703
+16% +$1.5M ﹤0.01% 1654
2022
Q4 		$6.07M Buy
796,119
+24,463
+3% +$234K ﹤0.01% 2122
2022
Q3 		$7.67M Sell
771,656
-298,503
-28% -$3.1M ﹤0.01% 1984
2022
Q2 		$9.72M Sell
1,070,159
-8,923
-0.8% -$74.6K ﹤0.01% 1845
2022
Q1 		$11M Buy
1,079,082
+33,792
+3% +$347K ﹤0.01% 1904
2021
Q4 		$17.4M Sell
1,045,290
-2,202
-0.2% -$93.2K 0.01% 1692
2021
Q3 		$49.1M Buy
1,047,492
+320,410
+44% +$17.2M 0.02% 878
2021
Q2 		$44.3M Buy
727,082
+37,550
+5% +$2.14M 0.01% 960
2021
Q1 		$42.5M Buy
689,532
+161,089
+30% +$10.5M 0.02% 951
2020
Q4 		$37.6M Buy
528,443
+5,900
+1% +$285K 0.01% 964
2020
Q3 		$19.6M Buy
522,543
+264,132
+102% +$8.31M 0.01% 1219
2020
Q2 		$8.43M Buy
258,411
+3,693
+1% +$112K ﹤0.01% 1745
2020
Q1 		$7.39M Buy
254,718
+121,687
+91% +$3.77M ﹤0.01% 1629
2019
Q4 		$4.66M Buy
133,031
+6,788
+5% +$188K ﹤0.01% 2051
2019
Q3 		$2.71M Buy
+126,243
New +$3.49M ﹤0.01% 2278

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Charles Schwab's BBIO Position: Q2 2026 in Review

Charles Schwab reduced its BridgeBio Pharma (BBIO) stake by 13% in Q2 2026, selling an estimated $18.7M and leaving 1,709,417 shares worth $127M. The position accounts for 0.02% of the portfolio, ranked #648.

Charles Schwab first reported a position in BBIO in Q3 2019 and has held it in 28 quarters since. The position peaked at $150M in Q4 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Charles Schwab held 1,709,417 shares of BridgeBio Pharma worth $127M as of Q2 2026.
  • Charles Schwab sold 266,677 BridgeBio Pharma shares in Q2 2026, an estimated $18.7M.
  • BridgeBio Pharma made up 0.02% of Charles Schwab's portfolio in Q2 2026, its #648 holding.
  • Charles Schwab first reported a position in BridgeBio Pharma in Q3 2019 and has held it in 28 quarters since.
  • Charles Schwab's BridgeBio Pharma position peaked at $150M in Q4 2025.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.